| Identification | Back Directory | [Name]
Tallimustine | [CAS]
115308-98-0 | [Synonyms]
FCE-24517
Talimustine
Tallimustine
Tallimustine USP/EP/BP
N-[5-[[(3-Amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[4-[bis(2-chloroethyl)amino]benzoylamino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide
1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl- | [Molecular Formula]
C32H38Cl2N10O4 | [MOL File]
115308-98-0.mol | [Molecular Weight]
697.624 |
| Hazard Information | Back Directory | [Uses]
Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4]. | [in vivo]
Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice[4].
| Animal Model: | L1210 tumor bearing mice[2]. | | Dosage: | 3 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Prolonged the survival of mice. |
| [References]
[1] Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38(42):14045-55. DOI:10.1021/bi991286r
[2] Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113(4):951-61. DOI:10.1046/j.1365-2141.2001.02843.x
[3] Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62(2):170-5. DOI:10.1002/ijc.2910620211
[4] Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33(2):284-7. DOI:10.1016/s0959-8049(96)00435-2 |
|
|